Gene-Targeted Electric Stimulation
Unlike traditional stimulation technologies that rely on broad, nonspecific signals, Vira Regen’s platform targets genetic drivers of repair with molecular precision
Applying gene-targeted bioelectric stimulation directly at the site of injury precisely enables dynamic modulation of therapeutic gene expression on demand – targeting the genetic drivers of repair directly, rather than indiscriminately stimulating tissue.
Vira Regen’s primary focus is in bone regeneration, prioritizing early studies in fresh and nonunion fractures.
Unlocking regenerative potential through electroceuticals to amplify the body’s natural healing response.
By integrating transcriptomic profiling, bioinformatics, and precision-engineered signal design, Vira Regen’s electroceutical platform selectively activates regenerative pathways that translate into meaningful, functional tissue repair and increased efficacy.
Most bioelectronic companies utilize electric stimulation for neuromodulation; Vira utilizes electric stimulation for gene modulation for tissue regeneration and enhanced therapeutic effect.
Modulating gene-expression on-demand to accelerate bone remodeling and repair
Vira Regen’s first product will be a novel, gene-targeted bone growth stimulator as a more effective frontline treatment for civilian and military health use.
Vira Regen’s OsteoVolt Bone Regeneration Solution offers a noninvasive electric stimulation treatment option, with early studies showing faster accelerated fracture healing with more robust preclinical data established compared to competitors.
In-vitro studies have shown Vira Regen’s ability to selectively modulate OPG and TGFB-1, two key genes in the osteogenic cascade.
In pre-clinical studies, this targeted modulation has demonstrated enhanced bone density, faster union, and more complete structural recovery compared to traditional, non-specific methods. Today, a non-GLP large animal study is underway.
